| PERUSINI, MA., K. PAGNANO, C. PAVLOVSKY, K. PAGNANO, B. MOIRAGHI, AI. VARELA, M. BIANCHINI, Jiří MAYER, Daniela ŽÁČKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, ABP. LOPES, G. DUARTE, CA. SOUZA, J. MEDEIROS, TS. KIM, YS. YOO, KH. KIM, HW. LEE, MH. CHANG, SY. YI, S. ABELSON and D. KIM. Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure. In 64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood. 2022. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{2241222,
author = {Perusini, MA. and Pagnano, K. and Pavlovsky, C. and Pagnano, K. and Moiraghi, B. and Varela, AI. and Bianchini, M. and Mayer, Jiří and Žáčková, Daniela and Kvetková, Anežka and Jurček, Tomáš and Ježíšková, Ivana and Lopes, ABP. and Duarte, G. and Souza, CA. and Medeiros, J. and Kim, TS. and Yoo, YS. and Kim, KH. and Lee, HW. and Chang, MH. and Yi, SY. and Abelson, S. and Kim, D.},
booktitle = {64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood},
title = {Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure},
year = {2022}
}
TY - CONF
ID - 2241222
AU - Perusini, MA. - Pagnano, K. - Pavlovsky, C. - Pagnano, K. - Moiraghi, B. - Varela, AI. - Bianchini, M. - Mayer, Jiří - Žáčková, Daniela - Kvetková, Anežka - Jurček, Tomáš - Ježíšková, Ivana - Lopes, ABP. - Duarte, G. - Souza, CA. - Medeiros, J. - Kim, TS. - Yoo, YS. - Kim, KH. - Lee, HW. - Chang, MH. - Yi, SY. - Abelson, S. - Kim, D.
PY - 2022
TI - Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure
ER -
PERUSINI, MA., K. PAGNANO, C. PAVLOVSKY, K. PAGNANO, B. MOIRAGHI, AI. VARELA, M. BIANCHINI, Jiří MAYER, Daniela ŽÁČKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, ABP. LOPES, G. DUARTE, CA. SOUZA, J. MEDEIROS, TS. KIM, YS. YOO, KH. KIM, HW. LEE, MH. CHANG, SY. YI, S. ABELSON and D. KIM. Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure. In \textit{64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood}. 2022.
|
